Fujifilm adding $120M facility to its gene therapy operations in U.S.
Fujifilm is continuing its aggressive expansion efforts with a major investment in its U.S. gene therapy operation by making a $120M addition to its Texas facilities. The company’s CDMO, Fujifilm Diosynth Biotechnologies, will add a building to its Dallas campus and intends to add 75 to 100 more scientists when the first phase of the project is ready in 2021.
They expect their CDMO business to generate nearly $1B by the end of fiscal year 2021, ending March 2022.
